High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline

High-risk stage IIB Hodgkin lymphoma treated in the H10 and AHL2011 trials: total metabolic tumor volume is a useful risk factor to stratify patients at baseline

Stage IIB Hodgkin lymphoma (HL) patients, with a mediastinum-to-thorax (M/T) ratio of ≥0.33 or extranodal localization have a poor prognosis and are treated either as limited or advanced stage. We compared these two approaches in patients included in two randomized phase III trials enrolling previo...

Full description

Bibliographic Details
Main Authors: Cédric Rossi, Marc André, Jehan Dupuis, Franck Morschhauser, Bertrand Joly, Julien Lazarovici, Hervé Ghesquières, Aspasia Stamatoullas, Emmanuelle Nicolas-Virelizier, Pierre Feugier, Anne-Claire Gac, Hannah Moatti, Luc-Matthieu Fornecker, Bénédicte Deau, Clémentine Joubert, Catherine Fortpied, John Raemaekers, Massimo Federico, Salim Kanoun, Michel Meignan, Alexandra Traverse-Glehen, Anne-Ségolène Cottereau, René-Olivier Casasnova
Format: Article
Language:English
Published: Ferrata Storti Foundation 2022-05-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/10671

Internet

https://haematologica.org/article/view/10671

Similar Items